ClinicalTrials.gg
RecruitingNCT07854431Updated Oct 2, 2026

CHECK-NIRS2D-Study

An observational study in NIRS, Tissue Oxygenation and Microvascular Perfusion, sponsored by Heinrich-Heine University, Duesseldorf. Recruiting at 1 site in Germany. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Heinrich-Heine University, Duesseldorf · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
20 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Ischemia with a site in Germany — 6 open to participants now, 9 under way, 1 of them phase 3. Ischemia · Germany.

Planned enrollment
14th of 15
20 · median 119
Started
2026
with 1 other
Observational
15 of 46
4 open now
Registered
46th of 46
by date

Among the 46 studies in Ischemia with a site in Germany, this one is the 14th largest by planned enrollment of the 15 observational ones that give a count, is one of 2 that started in 2026, is one of 15 observational ones, and was the 46th registered.

Ischemia

545 studies on the registry are indexed under Ischemia; 71 are open to participants now.

Browse Ischemia studies →

Open to participants now

6 of the 46 studies in Ischemia with a site in Germany are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 44 Ischemia studies recruiting now, 34 (77%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 20 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Ischemia with a site in Germany, or all of them as a file.
02

Study summary

The study investigates how external, physiological, and behavioral factors influence the measurement of regional tissue oxygenation using two-dimensional near-infrared spectroscopy (NIRS) imaging in healthy volunteers. It aims to improve the standardization and reliability of this non-invasive method for assessing microvascular perfusion and tissue oxygenation.

The study also examines the effects of temporary vascular occlusion, ambient temperature, physical activity, caffeine consumption, and nicotine consumption on NIRS-based tissue oxygenation measurements. The findings are intended to establish a standardized measurement protocol for future clinical research and the assessment of microvascular perfusion in critically ill patients.

Read the detailed description

The study is a prospective, monocentric, controlled experimental study in healthy volunteers. It examines how external conditions, physiological states, and everyday behaviors influence measurements obtained with two-dimensional near-infrared spectroscopy (2D-NIRS). The imaging method is intended to assess local tissue oxygenation and microvascular perfusion non-invasively.

Detailed study description

  1. General purpose

    The CHECK-NIRS2D study is a prospective, monocentric, controlled experimental study conducted at the University Hospital Düsseldorf. It investigates how external conditions, physiological states, and behavioral factors influence measurements of local tissue oxygenation obtained using two-dimensional near-infrared spectroscopy (2D-NIRS).

    The study uses the SnapshotNIR camera system (KD203, Kent Imaging Inc., Calgary, Canada). This non-invasive method produces spatially resolved images of tissue oxygenation, allowing the investigators to examine not only the overall oxygenation of a tissue region but also possible differences in perfusion between individual areas.

    The study is intended as physiological and methodological research. It does not evaluate the therapeutic efficacy or safety of the device and does not provide a direct medical benefit to participants. Its longer-term objective is to develop a standardized protocol for future studies involving patients with acute or chronic diseases, particularly in emergency and intensive-care medicine.

  2. Participants

    The study plans to include healthy adults:

    • Age: 20-40 years
    • Male and female participants
    • Voluntary written informed consent after detailed explanation
    • No acute illness at the time of examination
    • No relevant cardiovascular, pulmonary, renal, vascular, or neurological history
    • No relevant disease, previous surgery, or acute pathology affecting the examined upper limb
    • Resting oxygen saturation of at least 95%
    • No relevant resting hypotension or hypertension

    Participants who regularly use medication affecting the cardiovascular system or blood coagulation, as well as pregnant or breastfeeding participants, are excluded.

    Five substudies, designated A-E, are planned. Approximately 20 participants per experimental group are intended. Participants may take part in more than one substudy, but this is voluntary. The order of experimental protocols is randomized, and a recovery period of at least 60 minutes is planned between measurements of the same extremity, except where the caffeine- and nicotine-specific protocols require a different arrangement.

  3. General examination procedure

The examinations generally take place with the participant sitting upright. The arm to be examined is positioned beside the body, with the palm facing upwards and the elbow approximately at the level of the lower end of the sternum.

The following measurements are generally performed:

  • 2D-NIRS imaging of the hand or upper extremity
  • Measurement of regional and microvascular tissue oxygenation.
  • Repeated imaging during baseline, temporary ischemia, and reperfusion.
  • Vascular occlusion test (VOT)
  • A pneumatic blood-pressure cuff is inflated to 200 mmHg.
  • The radial pulse is checked at one-minute intervals to confirm interruption of arterial blood flow.
  • Depending on the protocol, the occlusion lasts three, five, or six minutes.
  • The cuff is then deflated, allowing reperfusion of the extremity.
  • Blood-pressure measurement
  • Systolic blood pressure
  • Diastolic blood pressure
  • Mean arterial pressure
  • Pulse oximetry
  • Measurement of peripheral oxygen saturation, or SpO₂.
  • Heart-rate measuremen
  • Capillary reperfusion time
  • Assessment of the time required for capillary perfusion to return.
  • Subjective pain assessment
  • Pain or discomfort during the vascular occlusion test is recorded using a Numeric Rating Scale (NRS).
  • Confocal retinal funduscopy
  • In specified experimental groups, the retinal microcirculation is examined using fully automated, confocal funduscopy.

Depending on the substudy, this is performed at baseline and at the end of the experiment or repeatedly during control measurements.

During the standard VOT protocols, heart rate, blood pressure, SpO₂, and pain are generally recorded at one-minute intervals. NIRS imaging and capillary reperfusion measurements are performed at shorter intervals during ischemia and early reperfusion, including every 30 seconds during ischemia and during the first five minutes after reperfusion begins.

The protocol includes:

  • Smokers and non-smokers
  • VOT and control conditions
  • Measurements after abstinence
  • A specific acute nicotine-exposure condition in smokers
  • NIRS imaging, VOT-related measurements, blood pressure, heart rate, SpO₂, pain assessment, and capillary reperfusion measurements are performed. In selected groups, retinal funduscopy is conducted at the beginning and end of the experiment.
03

Conditions studied

  • NIRS
  • Tissue Oxygenation
  • Microvascular Perfusion
  • Vascular Occlusion Test
  • Ischemia-reperfusion
  • Healty Volunteers
  • Physiological and Behavioral Factors
  • Temperature
  • Caffeine
  • Nicotine
  • Microcirculation
  • Protocol Standardization

Browse trials for

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

healthy volunteers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers aged 20-40 years
  • Written
  • Ability to understand and comply with the study procedures

Exclusion criteria

Exclusion Criteria:

  • Age below 20 years or above 40 years
  • Cardiovascular disease or other relevant medical conditions
  • current medication, where relevant to the study procedures
  • to or inability to undergo the planned examinations
  • Any condition that may interfere with the study procedures or outcome measurements
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Intervention

    predefined measurements

  • Control Group

    Standardized 2D-NIRS imaging at rest under predefined reference conditions, including the protocol-defined VOT.

06

What researchers measure

Primary outcomes

  1. microvascular tissue oxygenation

    StO₂, expressed as a percentage

    Time frame: within 20 Minutes of ischemia/reprefusion protocol measurement

Secondary outcomes

  1. Retinal funduscopy parameters

    measured by NIRS

    Time frame: within 20 Minutes of ischemia/reprefusion protocol measurement

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Mar 2027, 7 months after the start.

Of 48 non-industry observational studies under Ischemia, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 24. This study's planned 7 months is below that.

Counting every sponsor, half of 70 studies reached it within 35 months; a quarter within 22 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Jul 28, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854431
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Jul 28, 2026
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Patricia Wischmann, MD
Contact
patricia.wischmann@med.uni-duesseldorf.de
+49211 18000
Malte Kelm, MD
study chair · Division of Cardiology, Pulmonary Disease and Vascular Medicine at University Hospital Duesseldorf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion